Professor Clarke
Prof Stephen Clarke

OAM, Professor of Medicine, Medicine, Northern Clinical School, Kolling Institute, Member of China Studies Centre

A/Prof Anubhav Mittal

Gallbladder, hernia, pancreatic, and retroperitoneal surgeon. Director - Clinical/Surgical Skills, Surgery: Northern Clinical School  

Prof Jaswinder Samra

Clinical Professor, Discipline of Surgery: Northern Clinical School

Prof Anthony Gill

Surgical Pathologist, Professor of Surgical Pathology, University of Sydney

A/Prof Roderick Clifton-Bligh

Associate Professor, Medicine, Northern Clinical School, Kolling Institute

Prof Mark Sywak

Endocrine Surgeon, Clinical Associate Professor, Surgery: Northern Clinical School

Professor Bruce Robinson and Associate Professor Roderick Clifton-Bligh (Northern Clinical School, Kolling Institute) and their team have conducted several successful Pharamceutical Company sponsored clinical trials into the treatment of Medullary and Differentiated thyroid cancers which are metastatic, progressing and do not respond to standard treatment.

In 2006 the team began trialling Vandetanib, a drug used to treat patients with medullary thyroid cancer, a rare malignancy stemming from parafollicular C cells which produce calcitonin in the thyroid gland.

Vandetanib was deemed as an effective means to treat Medullary thyroid cancer and was consequently made available through prescription although not on the PBS.

In 2009 the team began studies using Lenvatinib to treat Medullary and Differentiated Thyroid Cancers resulting in Lenvatinib being made available to patients with Differentiated Thyroid cancer on the PBS.

The team is currently working on a number of other Clinical trials, including:

  • The ongoing study of Cabozantinib for patients with Medullary Thyroid Cancer
  • Their first ever phase one trial for a new medication, Loxo 292 in Medullary Thyroid Cancer
  • An important study measuring the best starting dosage of Lenvatinib in Differentiated Thyroid Cancer.

The centre and its team of surgeons, researchers and endocrinologists are renowned for their work towards the treatment of thyroid diseases and receive a high volume of referrals as a result.

TCE 3 – Breast Cancer Implementation

TCE Leaders:

Professor Frances BoyleMater Hospital

Professor Andrew SpillaneMater HospitalBreast and Surgical Oncology at The Poche Centre

Elizabeth Hutchings; University of Sydney (Northern Clinical School)

Elizabeth Hutchings

Doctor of Philosophy candidate at the University of Sydney (Northern Clinical School)

Prof Andrew Spillane

Surgical Oncologist, Associate Professor, Surgery, Northern Clinical School

Prof Fran Boyle

Professor of Medical Oncology & Director of Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital

A/Prof Nick Pavlakis

Medical Oncologist, Associate Professor, Medicine, Northern Clinical School

TCE 5 – Glioblastoma

TCE Leaders:

Prof Michael BackSNOG

Prof Helen WheelerSNOG

Dr Mustafa Khasraw

A/Prof Michael Back

Director of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital Medicine

A/Prof Helen Wheeler

Medical Oncologist, special interest in neuro-oncology and clinical trials

Dr Mustafa Khasraw

Oncology Senior Research Fellow and Clinical Lead, NHMRC Clinical Trials Centre, Sydney Medical School and Medical Oncologist

Professor Clarke
Prof Stephen Clarke

OAM, Professor of Medicine, Medicine, Northern Clinical School, Kolling Institute, Member of China Studies Centre

A/Prof Kellie Charles

Senior Lecturer, Pharmacology, School of Medical Sciences, Bosch Institute

Prof Alexander Engel

Centre Director, Sydney Vital, Head of Colorectal Surgical Unit, RNSH, Professor of Surgery

TCE 7 – Adrenocortical Cancer

TCE Leaders:

Professor Stan SidhuDr Stan Sidhu

Prof Stan Sidhu

Professor Surgery, Northern Clinical School, Kolling Institute

“Adrenal cancer is an extremely rare cancer with limited treatment options and poor survival rates. We are working on a new drug therapy which directly kills the cancer cells, stops the cancer spreading and reduces the risk of damage to other organs, including the liver.”

Professor Stan Sidhu
Professor of Surgery at the Northern Clinical School and Kolling Institute of Medical Research



Prof Stan Sidhu (Professor of Surgery, Head of the University of Sydney Endocrine Surgical Unit) and his team have conducted a clinical trial; A study of EnGeneIC Dream Vectors (EDV’s) packaged with the chemotherapy PNU-159682, given simultaneously as non-targeted EDVs carrying an immune enhancer called EDVs40-mer, in participants with advanced cancer who have no curative treatment options.

Trail ID: ACTRN12617000037303